Clinical utility of the 21-gene Oncotype DX® Recurrence Score® (RS) assay in hormone receptor-positive, HER2-negative breast cancer (BC). (March 2017) - Lau, A.; Miller, D.; Davison, D.; Rothney, M.; Borgen, P.